Comorbidities of Osteoporosis: Recent Advances and Early Screening

doi:10.12114/j.issn.1007-9572.2022.0425

Chinese General Practice ›› 2022, Vol. 25 ›› Issue (35): 4369-4374.DOI: 10.12114/j.issn.1007-9572.2022.0425

• Monographic Research·Comorbidity • Previous Articles Next Articles

Comorbidities of Osteoporosis: Recent Advances and Early Screening

¹Wangjing Hospital of Chinese Academy of Traditional Chinese Medicine, Beijing 100102, China
²Beijing Institute of Orthopaedical Traumatology of the Integrating of Traditional and Western Medicine, Beijing 100700, China
³School of Traditional Chinese Medicine & School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China
⁴Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China

Received:2022-05-15 Revised:2022-07-12 Published:2022-12-15 Online:2022-08-04
Contact: XIE Yanming, ZHU Liguo
About author:
WEI X, LIU N, ZHANG Y L, et al. Comorbidities of osteoporosis: recent advances and early screening[J]. Chinese General Practice, 2022, 25 (35) : 4369-4374.

骨质疏松症的共病研究与早期筛查

¹100102　北京市，中国中医科学院望京医院
²100700　北京市中西医结合骨伤研究所
³210023　江苏省南京市，南京中医药大学中医学院·中西医结合学院
⁴100700　北京市，中国中医科学院中医临床基础医学研究所

通讯作者: 谢雁鸣, 朱立国
作者简介:
魏戌，刘宁，章轶立，等.骨质疏松症的共病研究与早期筛查[J].中国全科医学，2022，25（35）：4369-4374.[www.chinagp.net] 作者贡献：魏戌、谢雁鸣、朱立国进行文章的整体构思与设计；魏戌、刘宁、章轶立进行文献收集、整理，完成论文撰写；韩涛、孙凯、齐保玉、陈忻、秦晓宽进行文章的修订；高景华、谢雁鸣、朱立国负责文章的质量控制及审校，对文章整体负责与监督管理。
基金资助:
国家中医药管理局传承创新团队项目(ZYYCTXD-C-202003); 中国中医科学院科技创新工程重大攻关项目(CI2021A02013); 中国中医科学院循证医学中心业务研究室主任专项(2020YJSZX-4); 中国中医科学院优秀青年科技人才（创新类）培养专项(ZZ13-YQ-039)

Abstract

Abstract:

Comorbidities are highly prevalent in osteoporosis patients, including endocrine, circulatory, respiratory, urinary, immune, musculoskeletal, and neurological diseases, which may aggravate osteoporosis, increase the risk of osteoporotic fracture, and seriously affect the quality of patient's life, bringing more challenges to associated clinical management, and imposing a heavy burden on the families and society. There is still a lack of studies on comorbidities of osteoporosis, and the existing research strategies are inadequate to support clinicians to carry out comorbidity management in terms of understanding the causes of osteoporosis and associated comorbidities, and delivering interventions for prevention and treatment of both of them. In view of this, it is suggested to use multidisciplinary integrated treatment, and strengthen the understanding of osteoporosis related comorbidities and their pathogenesis. Moreover, the screening for osteoporosis in people with possible osteoporosis risk should be performed as early as possible, and actions should be taken actively to reduce the risk of fracture in those who are found with osteopenia or osteoporosis. Early screening, diagnosis and treatment are necessary to realize the prevention and treatment of osteoporosis and associated comorbidities.

Key words: Osteoporosis, Comorbidity, Osteoporotic fractures, Diagnosis, Pathogenic mechanism, Multidisciplinary integrated treatment, Early screening

摘要：

骨质疏松症患者常共患多种疾病，涉及内分泌、循环、呼吸、泌尿、免疫、骨骼肌肉、神经等多系统疾病，共病发生率较高，且这些共病可能会加重骨质疏松症，从而增加骨质疏松性骨折发生的风险，严重影响患者生活质量，同时使疾病管理更加复杂，给家庭和社会带来沉重负担。目前对于骨质疏松症共病的研究较为缺乏，现有的研究策略在共因、共防、共治方面难以有效指导临床医生开展共病管理。鉴于此，建议引入多学科综合治疗（MDT）理念，加强骨质疏松症相关共病及其致病机制的认识，对于可能合并骨质疏松症的患者需尽早筛查，一旦发现骨量减少、骨质疏松，应积极进行防治以降低骨折风险，早筛、早诊、早治，实现骨质疏松症共病的共防、共治。

关键词: 骨质疏松, 共病现象, 骨质疏松性骨折, 诊断, 发病机制, 多学科综合治疗, 早期筛查

WEI Xu,LIU Ning,ZHANG Yili, et al. Comorbidities of Osteoporosis: Recent Advances and Early Screening[J]. Chinese General Practice, 2022, 25(35): 4369-4374. DOI: 10.12114/j.issn.1007-9572.2022.0425.
魏戌,刘宁,章轶立等. 骨质疏松症的共病研究与早期筛查[J]. 中国全科医学, 2022, 25(35): 4369-4374. DOI: 10.12114/j.issn.1007-9572.2022.0425.

References 52

[1]	FEINSTEIN A R. The pre-therapeutic classification of co-morbidity in chronic disease[J]. J Chronic Dis，1970，23（7）：455-468. DOI：10.1016/0021-9681(70)90054-8.
[2]	SALIVE M E. Multimorbidity in older adults[J]. Epidemiol Rev，2013，35：75-83. DOI：10.1093/epirev/mxs009.
[3]	SHARMA B，SINGH H，CHODHARY P，et al. Osteoporosis in otherwise healthy patients with type 2 diabetes：a prospective gender based comparative study[J]. Indian J Endocrinol Metab，2017，21（4）：535-539. DOI：10.4103/ijem.IJEM_108_17.
[4]	CORTET B，LUCAS S，LEGROUX-GEROT I，et al. Bone disorders associated with diabetes mellitus and its treatments[J]. Joint Bone Spine，2019，86（3）：315-320. DOI：10.1016/j.jbspin.2018.08.002.
[5]	GOLDSHTEIN I，NGUYEN A M，DEPAPP A E，et al. Epidemiology and correlates of osteoporotic fractures among type 2 diabetic patients[J]. Arch Osteoporos，2018，13（1）：15. DOI：10.1007/s11657-018-0432-x.
[6]	HULL B，SMITH N R. Diabetes and bone[J]. Am J Med Sci，2016，351（4）：356-360. DOI：10.1016/j.amjms.2016.02.010.
[7]	VALDERRABANO R J，LINARES M I. Diabetes mellitus and bone health：epidemiology，etiology and implications for fracture risk stratification[J]. Clin Diabetes Endocrinol，2018，4：9. DOI：10.1186/s40842-018-0060-9.
[8]	GOSWAMI R，NAIR A. Diabetes mellitus，vitamin D & osteoporosis：insights[J]. Indian J Med Res，2019，150（5）：425-428. DOI：10.4103/ijmr.IJMR_1920_19.
[9]	SCHARLA S. Diabetes mellitus and osteoporosis：who should be addressed and how to confirm the diagnosis[J]. MMW Fortschr Med，2018，160（21/22）：65-69. DOI：10.1007/s15006-018-1239-9.
[10]	YAMAMOTO M，YAMAUCHI M，SUGIMOTO T. Prevalent vertebral fracture is dominantly associated with spinal microstructural deterioration rather than bone mineral density in patients with type 2 diabetes mellitus[J]. PLoS One，2019，14（9）：e0222571. DOI：10.1371/journal.pone.0222571.
[11]	GIANGREGORIO L M，LESLIE W D，LIX L M，et al. FRAX underestimates fracture risk in patients with diabetes[J]. J Bone Miner Res，2012，27（2）：301-308. DOI：10.1002/jbmr.556.
[12]	PAPAIOANNOU I，PANTAZIDOU G，KOKKALIS Z，et al. Systematic review：are the elderly with diabetes mellitus type 2 prone to fragility fractures? [J]. Cureus，2021，13（4）：e14514. DOI：10.7759/cureus.14514.
[13]	IRVING J T. Calcification of the organic matrix of enamel[J]. Arch Oral Biol，1963，8：773-774. DOI：10.1016/0003-9969(63)90010-4.
[14]	MURCH O，COLLIN M，HINDS C J，et al. Lipoproteins in inflammation and Sepsis. I. Basic science[J]. Intensive Care Med，2007，33（1）：13-24. DOI：10.1007/s00134-006-0432-y.
[15]	LEKAMWASAM S，WEERARATHNA T，RODRIGO M，et al. Osteoporosis and cardiovascular risk among premenopausal women in Sri Lanka[J]. J Clin Densitom，2009，12（2）：245-250. DOI：10.1016/j.jocd.2009.02.001.
[16]	WANG Y M，ZHU Y，LU S D，et al. Beneficial effects of paeoniflorin on osteoporosis induced by high-carbohydrate，high-fat diet-associated hyperlipidemia in vivo[J]. Biochem Biophys Res Commun，2018，498（4）：981-987. DOI：10.1016/j.bbrc.2018.03.093.
[17]	TINTUT Y，DEMER L L. Effects of bioactive lipids and lipoproteins on bone[J]. Trends Endocrinol Metab，2014，25（2）：53-59. DOI：10.1016/j.tem.2013.10.001.
[18]	蔡晓燕，董光富. 脂代谢及血清骨钙素水平与骨质疏松症的相关性分析[J]. 中国骨质疏松杂志，2016，22（6）：711-712，730. DOI：10.3969/j.issn.1006-7108.2016.06.011.
[19]	CHEN S J，LIN C S，LIN C L，et al. Osteoporosis is associated with high risk for coronary heart disease：a population-based cohort study[J]. Medicine （Baltimore），2015，94（27）：e1146. DOI：10.1097/MD.0000000000001146.
[20]	李洁，杨希立，郭晋爱，等. 老年冠心病与骨质疏松的相关性研究[J]. 中国实用内科杂志，2010，30（S1）：20-23.
[21]	LAROCHE M，PECOURNEAU V，BLAIN H，et al. Osteoporosis and ischemic cardiovascular disease[J]. Joint Bone Spine，2017，84（4）：427-432. DOI：10.1016/j.jbspin.2016.09.022.
[22]	魏戌，章轶立，谢雁鸣，等. 骨质疏松症与冠心病共病患者的临床特征及其影响因素[J]. 中华骨质疏松和骨矿盐疾病杂志，2020，13（4）：318-325. DOI：10.3969/j.issn.1674-2591.2020.04.006.
[23]	BROUSSARD D L，MAGNUS J H. Coronary heart disease risk and bone mineral density among US women and men[J]. J Womens Health （Larchmt），2008，17（3）：479-490. DOI：10.1089/jwh.2007.0593.
[24]	PACCOU J，EDWARDS M H，WARD K，et al. Relationships between bone geometry，volumetric bone mineral density and bone microarchitecture of the distal radius and Tibia with alcohol consumption[J]. Bone，2015，78：122-129. DOI：10.1016/j.bone.2015.05.002.
[25]	YANG S，NGUYEN N D，CENTER J R，et al. Association between hypertension and fragility fracture：a longitudinal study[J]. Osteoporos Int，2014，25（1）：97-103. DOI：10.1007/s00198-013-2457-8.
[26]	AL-HARIRI M，ALDHAFERY B. Association of hypertension and lipid profile with osteoporosis[J]. Scientifica （Cairo），2020，2020：7075815. DOI：10.1155/2020/7075815.
[27]	VARENNA M，MANARA M，GALLI L，et al. The association between osteoporosis and hypertension：the role of a low dairy intake[J]. Calcif Tissue Int，2013，93（1）：86-92. DOI：10.1007/s00223-013-9731-9.
[28]	HU X L，SUN Y C，XU W H，et al. Expression of RANKL by peripheral neutrophils and its association with bone mineral density in COPD[J]. Respirology，2017，22（1）：126-132. DOI：10.1111/resp.12878.
[29]	WATANABE R，TAI N，HIRANO J，et al. Independent association of bone mineral density and trabecular bone score to vertebral fracture in male subjects with chronic obstructive pulmonary disease[J]. Osteoporos Int，2018，29（3）：615-623. DOI：10.1007/s00198-017-4314-7.
[30]	INOUE D，WATANABE R，OKAZAKI R. COPD and osteoporosis：links，risks，and treatment challenges[J]. Int J Chron Obstruct Pulmon Dis，2016，11：637-648. DOI：10.2147/COPD.S79638.
[31]	OZCAKIR S，SIGIRLI D，URSAVAS A，et al. COPD and osteoporosis：associated factors in patients treated with inhaled corticosteroids[J]. Int J Chron Obstruct Pulmon Dis，2020，15：2441-2448. DOI：10.2147/COPD.S274728.
[32]	BARNES P J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol，2016，138（1）：16-27. DOI：10.1016/j.jaci.2016.05.011.
[33]	ROMME E A，GEUSENS P，LEMS W F，et al. Fracture prevention in COPD patients；a clinical 5-step approach[J]. Respir Res，2015，16：32. DOI：10.1186/s12931-015-0192-8.
[34]	KINSELLA S，CHAVRIMOOTOO S，MOLLOY M G，et al. Moderate chronic kidney disease in women is associated with fracture occurrence independently of osteoporosis[J]. Nephron Clin Pract，2010，116（3）：c256-262. DOI：10.1159/000317207.
[35]	NITTA K，YAJIMA A，TSUCHIYA K. Management of osteoporosis in chronic kidney disease[J]. Intern Med，2017，56（24）：3271-3276. DOI：10.2169/internalmedicine.8618-16.
[36]	HSU C Y，CHEN L R，CHEN K H. Osteoporosis in patients with chronic kidney diseases：a systemic review[J]. Int J Mol Sci，2020，21（18）：6846. DOI：10.3390/ijms21186846.
[37]	MAZZAFERRO S，DE MARTINI N，ROTONDI S，et al. Bone，inflammation and chronic kidney disease[J]. Clin Chim Acta，2020，506：236-240. DOI：10.1016/j.cca.2020.03.040.
[38]	KETTELER M，BLOCK G A，EVENEPOEL P，et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder （CKD-MBD） Guideline Update：what's changed and why it matters[J]. Kidney Int，2017，92（6）：1558. DOI：10.1016/j.kint.2017.10.001.
[39]	LIU L C，LU M C，WANG S Y，et al. Association of use of rehabilitation services with development of osteoporosis among patients with rheumatoid arthritis：a nationwide population-based cohort study[J]. Osteoporos Int，2018，29（8）：1897-1903. DOI：10.1007/s00198-018-4569-7.
[40]	LINDNER L，CALLHOFF J，ALTEN R，et al. Osteoporosis in patients with rheumatoid arthritis：trends in the German National Database 2007-2017[J]. Rheumatol Int，2020，40（12）：2005-2012. DOI：10.1007/s00296-020-04593-6.
[41]	ADAMI G，SAAG K G. Osteoporosis pathophysiology，epidemiology，and screening in rheumatoid arthritis[J]. Curr Rheumatol Rep，2019，21（7）：34. DOI：10.1007/s11926-019-0836-7.
[42]	LLORENTE I，GARCÍA-CASTAÑEDA N，VALERO C，et al. Osteoporosis in rheumatoid arthritis：dangerous liaisons[J]. Front Med （Lausanne），2020，7：601618. DOI：10.3389/fmed.2020.601618.
[43]	SIMON D，KLEYER A，ENGLBRECHT M，et al. A comparative analysis of articular bone in large cohort of patients with chronic inflammatory diseases of the joints，the gut and the skin[J]. Bone，2018，116：87-93. DOI：10.1016/j.bone.2018.07.017.
[44]	FARDELLONE P，SALAWATI E，LE MONNIER L，et al. Bone loss，osteoporosis，and fractures in patients with rheumatoid arthritis：a review[J]. J Clin Med，2020，9（10）：E3361. DOI：10.3390/jcm9103361.
[45]	AL SALEH J，SAYED M E，MONSEF N，et al. The prevalence and the determinants of musculoskeletal diseases in emiratis attending primary health care clinics in Dubai[J]. Oman Med J，2016，31（2）：117-123. DOI：10.5001/omj.2016.23.
[46]	CLAYTON E S，HOCHBERG M C. Osteoporosis and osteoarthritis，rheumatoid arthritis and spondylarthropathies[J]. Curr Osteoporos Rep，2013，11（4）：257-262. DOI：10.1007/s11914-013-0172-1.
[47]	VRTACNIK P，ZUPAN J，MLAKAR V，et al. Epigenetic enzymes influenced by oxidative stress and hypoxia mimetic in osteoblasts are differentially expressed in patients with osteoporosis and osteoarthritis[J]. Sci Rep，2018，8（1）：16215. DOI：10.1038/s41598-018-34255-4.
[48]	GANGULY P，EL-JAWHARI J J，GIANNOUDIS P V，et al. Age-related changes in bone marrow mesenchymal stromal cells：a potential impact on osteoporosis and osteoarthritis development[J]. Cell Transplant，2017，26（9）：1520-1529. DOI：10.1177/0963689717721201.
[49]	曾展鹏，戴才锋，郑伟杰，等. 超声骨密度筛查膝关节骨性关节炎患者骨质疏松症的效果[J]. 实用医学杂志，2018，34（2）：243-246. DOI：10.3969/j.issn.1006-5725.2018.02.021.
[50]	CHENG B H，CHEN P C，YANG Y H，et al. Effects of depression and antidepressant medications on hip fracture：a population-based cohort study in Taiwan[J]. Medicine （Baltimore），2016，95（36）：e4655. DOI：10.1097/MD.0000000000004655.
[51]	WENG S F，HSU H R，WENG Y L，et al. Health-related quality of life and medical resource use in patients with osteoporosis and depression：a cross-sectional analysis from the national health and nutrition examination survey[J]. Int J Environ Res Public Health，2020，17（3）：E1124. DOI：10.3390/ijerph17031124.
[52]	ROSENBLAT J D，GREGORY J M，CARVALHO A F，et al. Depression and disturbed bone metabolism：a narrative review of the epidemiological findings and postulated mechanisms[J]. Curr Mol Med，2016，16（2）：165-178. DOI：10.2174/1566524016666160126144303.

Comorbidities of Osteoporosis: Recent Advances and Early Screening

骨质疏松症的共病研究与早期筛查

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 52

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Han, CAI Genshen, FENG Zhengwen, ZHANG Kaiyue, LIAN Dongbo, ZHANG Hua, ZHANG Jing. Evaluating the Availability of Health Services for Obesity Comorbidities under Hierarchical Diagnosis and Treatment in Beijing: a Healthcare Institution Survey Study [J]. Chinese General Practice, 2026, 29(28): 4117-4124.
[2]	LI Zhixin, LIU Xiaoyu. Practical Research on Promoting Hierarchical Diagnosis and Treatment Through Collaborative Governance of Medical Quality in Regional Medical Alliance [J]. Chinese General Practice, 2026, 29(28): 4107-4116.
[3]	FU Xiaoya, YANG Fei, GU Keyi, GU Handong, WANG Weiqiang. Correlation between Relative Fat Mass Index and Decreased Glomerular Filtration Rate in Patients with Cardiometabolic Comorbidities [J]. Chinese General Practice, 2026, 29(28): 4187-4192.
[4]	LU Hongrun, ZHANG Rui, ZHAO Yu, LI Jiazhen, WANG Weiqiang. Association of Cardiometabolic Comorbidity with Estimated Glomerular Filtration Rate [J]. Chinese General Practice, 2026, 29(28): 4179-4186.
[5]	ZHANG Ying, TANG Yijun, LIU Lidi, JIANG Lihua, JIA Yu, YANG Rong, YANG Ziyu, LIAO Xiaoyang. Management of Cardiovascular Metabolic Risks in Obese Children and Adolescents in China: Based on the 2024 Italian Society of Pediatric Endocrinology and Diabetes Position Paper on Cardiometabolic Risk in Children and Adolescents with Obesity [J]. Chinese General Practice, 2026, 29(27): 3879-3887.
[6]	WU Yuqiong, CHU Xiangling, HUANG Youye, SUN Li, JIANG Tian, ZHANG Qiu, HU Honglin. A Case Report and Literature Review of Hepatocyte Nuclear Factor 4α Gene Mutation Leading to Maturity-onset Diabetes of the Young [J]. Chinese General Practice, 2026, 29(27): 4011-4015.
[7]	FENG Yachen, LIU Lewei, XUE Jinyue, SUN Xianlin, LIU Huanzhong. Research Progress of Wearable Technology in the Diagnosis and Treatment of Mental Disorders [J]. Chinese General Practice, 2026, 29(27): 4016-4025.
[8]	FENG Shaohui, ZHU Lingyan, SONG Kexin, ZHU Yan, WU Yanling, WU Wenjing, ZHANG Dandan, RAN Limei. Study on the Relationship between Relevant Indicators in Postmenopausal Women with Subclinical Hypothyroidism and Bone Mineral Density [J]. Chinese General Practice, 2026, 29(26): 3774-3780.
[9]	LIU Yahui, XU Yanan, YUAN Ling, WU Ligui, ZHOU Yujie, KANG Yubiao. A Scoping Review on Triage for Palliative Care Patients Based on Priority Decision-making [J]. Chinese General Practice, 2026, 29(24): 3538-3544.
[10]	LIN Yanping, HUANG Jiachun, GUO Haiwei, ZHAO Rui, YANG Haolin, WAN Lei, ZHU Genfu, HUANG Hongxing. Study on the Distribution of TCM Syndrome Types and the Relationship between Muscle-bone-lipid in Patients with Primary Osteoporosis [J]. Chinese General Practice, 2026, 29(21): 3040-3045.
[11]	PAN Ziyun, YIN Hao, LIN Zhirou, MAO Jingyi, HUANG Yan, LUO Yanhua, XIAO Jiafu, HU Yin. From Mechanism to Therapy: Diabetic Autonomic Neuropathy [J]. Chinese General Practice, 2026, 29(21): 2982-2988.
[12]	YAN Wen, ZHANG Hanzhi, JIN Hua, QIAN Jie, YU Dehua. Study on the Diagnosis and Treatment Capacity for Depressive Disorders in Community Health Service Institutions in Shanghai [J]. Chinese General Practice, 2026, 29(20): 2790-2799.
[13]	General Practice Branch of Cross-straits Medicine Exchange Association, General Practice Branch of Zhejiang Medical Association, General Undifferentiated Disease Professional Committee of Zhejiang Society of Mathematical Medicine, Chinese Geriatrics Society. Expert Consensus on the Diagnosis, Treatment, and Management of Numbness (2025) [J]. Chinese General Practice, 2026, 29(18): 2433-2449.
[14]	FAN Meixiang, YAN Yunyun, HUANG Yanyan. Interpretation and Discussion of Guidelines for Preventive Activities in General Practice: Bladder Cancer [J]. Chinese General Practice, 2026, 29(18): 2450-2453.
[15]	CHEN Yiping, ZHANG Jianmei, LI Yanhu, LI Rui, ZHANG Ruiping, YANG Ping. Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury [J]. Chinese General Practice, 2026, 29(18): 2585-2592.